Vorasidenib

Vorasidenib
Clinical data
ATC code	None;
Identifiers
	IUPAC name 6-(6-Chloropyridin-2-yl)-2-N,4-N-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine;
CAS Number	1644545-52-7;
PubChem CID	117817422;
IUPHAR/BPS	10663;
DrugBank	DB17097;
ChemSpider	64835242;
UNII	789Q85GA8P;
ChEMBL	ChEMBL4279047;
Chemical and physical data
Formula	C14H13ClF6N6
Molar mass	414.74 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@H](C(F)(F)F)NC1=NC(=NC(=N1)C2=NC(=CC=C2)Cl)N[C@H](C)C(F)(F)F;
	InChI InChI=1S/C14H13ClF6N6/c1-6(13(16,17)18)22-11-25-10(8-4-3-5-9(15)24-8)26-12(27-11)23-7(2)14(19,20)21/h3-7H,1-2H3,(H2,22,23,25,26,27)/t6-,7-/m1/s1; Key:QCZAWDGAVJMPTA-RNFRBKRXSA-N;

Vorasidenib is an experimental anti-cancer medication for the treatment of low-grade glioma. It is a small molecule inhibitor of isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2), which are mutated in several forms of cancer.^[1] In a phase-III-trial, it was shown to prolong progression-free survival in patients with IDH1- or IDH2-mutant low-grade glioma.^[2]

References

↑ "Vorasidenib compound summary". pubchem. 2 September 2023. Retrieved 6 September 2023.
↑ Mellinghoff, Ingo K.; et al. (2023-08-17), "Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma", New England Journal of Medicine, vol. 389, no. 7, pp. 389–601, doi:10.1056/NEJMoa2304194, PMC 5900343, PMID 29670690

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.